What's Behind Incyte's Better-Than-Expected Q4 Earnings
Several products contributed to the biotech's solid growth.
The Company is a drug discovery and development company focused on developing proprietary small molecule drugs to treat serious unmet medical needs.
Several products contributed to the biotech's solid growth.
INCY earnings call for the period ending February 9, 2021.
Investors should take notice of this four-way competition.
INCY earnings call for the period ending September 30, 2020.
INCY earnings call for the period ending June 30, 2020.
Incyte might finally be convincing Wall Street that its pipeline is the real deal.
INCY earnings call for the period ending March 31, 2020.
The biotech's revenue increased solidly in Q1. And it had a very good explanation for its net loss.
The biotech's revenue soared thanks to the continued success of Jakafi, but its bottom line was weighed down by a licensing deal.
Is the biotech company worth its rich valuation metrics?